Table 2.
Moderate or severe symptoms at baseline
| ASC (N=136) | ASC+MVP (N=137) | ASC+V (N=136) | |
|---|---|---|---|
| As reported by clinicians | |||
| Lethargy | 26/132 (20%) | 37/135 (27%) | 32/134 (24%) |
| Chest pain | 36/132 (27%) | 29/135 (21%) | 28/133 (21%) |
| Sweating | 22/132 (17%) | 16/135 (12%) | 19/133 (14%) |
| Anorexia | 18/132 (14%) | 20/135 (15%) | 17/134 (13%) |
| Cough | 15/132 (11%) | 19/135 (14%) | 17/133 (13%) |
| Constipation | 17/132 (13%) | 18/135 (13%) | 13/134 (10%) |
| Other pain | 14/130 (11%) | 11/134 (8%) | 20/132 (15%) |
| MRC grade 4+ breathlessness* | 44/128 (34%) | 41/131 (31%) | 38/133 (29%) |
| As reported by patients with the QOL questionnaire | |||
| Shortness of breath | 49/126 (39%) | 46/126 (37%) | 42/124 (34%) |
| Tiredness | 45/126 (36%) | 37/125 (30%) | 37/122 (30%) |
| General pain | 43/127 (34%) | 35/127 (28%) | 32/124 (26%) |
| Worried | 37/126 (29%) | 22/127 (17%) | 23/123 (19%) |
| Chest pain | 31/125 (25%) | 28/127 (22%) | 21/124 (17%) |
| Cough | 28/126 (22%) | 26/128 (20%) | 23/125 (18%) |
| Sweating | 23/106 (22%) | 19/114 (17%) | 24/110 (22%) |
| Constipation | 29/127 (23%) | 26/127 (20%) | 18/124 (15%) |
ASC=active symptom control. MVP=mitomycin, vinblastine, and cisplatin. V=vinorelbine. QOL=quality of life.
*
Scored as follows: MRC grade: 1=climbs hills or stairs without dyspnoea; 2=walks any distance on the flat without dyspnoea; 3=walks over 100 m without dyspnoea; 4=dyspnoea on walking 100 m or less; 5=dyspnoea on mild exertion—eg, undressing; 6=dyspnoea at rest.